Avatar Posted by worldpharmanews 11 days ago (http://www.worldpharmanews.com)
Category: Product | Tags: boehringer ingelheim aptivus
Boehringer Ingelheim announced that the European Commission has given the full marketing authorisation to its HIV protease inhibitor (PI), Aptivus® (tipranavir). The Commission has fully approved Aptivus ® for the suppression of HIV in highly treatment experienced patients who have developed resistance to other protease inhibitors.
Discuss   Add this link to...  Bury

Comments Who Voted Related Links


Blogroll [ alliConnect | BioJobBlog | CNTO411 | Corey Nahman | eDrugSearch | Drug Injury Watch | EyeOnFDA | Forbes ScienceBiz | JNJ BTW | medGadget | Medical 2.0 | Pharma's Market at CNBC | PharmaFraud | PharmaGossip | Pharmalot | The Shark Report | World Pharma News | WSJ Health Blog ]
Pharmaceutical Companies [ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

About | Buttons | Contact | Terms and Conditions
Concept and Design by World Pharma News (.com) Project | Powered by Pligg based on PHP/MySQL.
Submit to World Pharma News .net